Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount for treating hypertrophy of a combination of a compound selected from the group consisting of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, and a therapeutic cardiovascular compound selected from the group consisting of a calcium channel blocker, a β-adrenergic receptor antagonist, a vasodilator, a diuretic, an α-adrenergic receptor antagonist, an antioxidant, and a mixture thereof,
wherein the 3-acylated pyridoxal analogue is a compound of the formula



or



wherein

R_1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

R_2 is a secondary amino group.

2-5. (cancelled)

6. (previously presented) The method of claim 1, wherein the calcium channel blocker is verapamil, diltiazem, nicardipine, nifedipine, amlodipine, felodipine, nimodipine, or bepridil.

7. (previously presented) The method of claim 1, wherein the compound is administered enterally or parenterally and the therapeutic cardiovascular compound is administered enterally or parenterally.

8. (previously presented) The method of claim 1, wherein the compound and the therapeutic cardiovascular compound are administered in a single dosage form.

9. (previously presented) The method of claim 1, wherein the β-adrenergic receptor antagonist is atenolol, propranolol, timolol or metoprolol.

10. (previously presented) The method of claim 1, wherein the diuretic is furosemide, diuril, amiloride or hydrodiuril.

11. (previously presented) The method of claim 1, wherein the α-adrenergic receptor antagonist is prazosin, doxazocin or labetolol.

12. (previously presented) The method of claim 1, wherein the antioxidant is vitamin E, vitamin C or an isoflavone.

13. (Currently Amended) A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective for treating hypertrophy amount of a combination of an angiotensin converting enzyme inhibitor and a compound selected from the group consisting of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, wherein the 3-acylated pyridoxal analogue is a compound of the formula



or



wherein

R_1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

R_2 is a secondary amino group.

14. (previously presented) The method according to claim 13, wherein the angiotensin converting enzyme inhibitor is captopril, enalapril, lisinopril, benzazpril, fosinopril, quinapril, ramipril, spirapril, imidapril, or moexipril.

15. (previously presented) A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount for treating hypertrophy of a combination of a an angiotensin II receptor antagonist and a compound selected from the group consisting of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, wherein the 3-acylated pyridoxal analogue is a compound of the formula



or



wherein

R_1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and
R_2 is a secondary amino group.

16. (previously presented) The method according to claim 15, wherein the angiotensin II receptor antagonist is losartan or valsartan.